Morgan Stanley
VKTX icon

Morgan Stanley’s Viking Therapeutics VKTX Stock Holding History

Morgan Stanley’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.1M Sell
3,013,928
-62,342
-2% -$2M 0.01% 1461
2025
Q4 		$108M Sell
3,076,270
-652,847
-18% -$23.1M 0.01% 1386
2025
Q3 		$98M Buy
3,729,117
+481,423
+15% +$14.4M 0.01% 1418
2025
Q2 		$86.1M Buy
3,247,694
+127,038
+4% +$3.34M 0.01% 1439
2025
Q1 		$75.4M Buy
3,120,656
+527,041
+20% +$16.7M 0.01% 1459
2024
Q4 		$104M Buy
2,593,615
+718,770
+38% +$41M 0.01% 1221
2024
Q3 		$119M Buy
1,874,845
+927,638
+98% +$54.4M 0.01% 1119
2024
Q2 		$50.2M Sell
947,207
-52,164
-5% -$3.42M ﹤0.01% 1749
2024
Q1 		$81.9M Sell
999,371
-2,026,891
-67% -$90.2M 0.01% 1329
2023
Q4 		$56.3M Buy
3,026,262
+2,135,580
+240% +$27.9M ﹤0.01% 2312
2023
Q3 		$9.86M Sell
890,682
-430,295
-33% -$6.15M ﹤0.01% 3143
2023
Q2 		$21.4M Buy
1,320,977
+442,366
+50% +$9.27M ﹤0.01% 2409
2023
Q1 		$14.6M Buy
878,611
+297,848
+51% +$3.08M ﹤0.01% 2766
2022
Q4 		$5.46M Buy
580,763
+181,522
+45% +$810K ﹤0.01% 3678
2022
Q3 		$1.09M Sell
399,241
-261,927
-40% -$858K ﹤0.01% 4835
2022
Q2 		$1.91M Buy
661,168
+304,664
+85% +$754K ﹤0.01% 4573
2022
Q1 		$1.07M Buy
356,504
+131,861
+59% +$473K ﹤0.01% 4941
2021
Q4 		$1.03M Sell
224,643
-33,096
-13% -$185K ﹤0.01% 5045
2021
Q3 		$1.62M Sell
257,739
-190,852
-43% -$1.18M ﹤0.01% 4738
2021
Q2 		$2.69M Buy
448,591
+326,954
+269% +$1.94M ﹤0.01% 4394
2021
Q1 		$770K Buy
121,637
+35,558
+41% +$250K ﹤0.01% 4891
2020
Q4 		$485K Sell
86,079
-256,645
-75% -$1.55M ﹤0.01% 5096
2020
Q3 		$1.99M Buy
342,724
+173,320
+102% +$1.19M ﹤0.01% 3662
2020
Q2 		$1.22M Buy
169,404
+89,521
+112% +$594K ﹤0.01% 4013
2020
Q1 		$373K Sell
79,883
-150,568
-65% -$926K ﹤0.01% 4546
2019
Q4 		$1.85M Buy
230,451
+87,097
+61% +$635K ﹤0.01% 4106
2019
Q3 		$987K Buy
143,354
+18,596
+15% +$138K ﹤0.01% 4307
2019
Q2 		$1.03M Sell
124,758
-20,174
-14% -$172K ﹤0.01% 4200
2019
Q1 		$1.44M Sell
144,932
-264,156
-65% -$2.21M ﹤0.01% 3852
2018
Q4 		$3.13M Buy
409,088
+250,538
+158% +$3M ﹤0.01% 3386
2018
Q3 		$2.76M Buy
158,550
+60,414
+62% +$719K ﹤0.01% 3737
2018
Q2 		$931K Buy
98,136
+85,255
+662% +$567K ﹤0.01% 4672
2018
Q1 		$56K Buy
+12,881
New +$71.3K ﹤0.01% 5861
2017
Q2 		– Sell
-398
Closed -$1K – 6659
2017
Q1 		$1K Sell
398
-15,241
-97% -$21.3K ﹤0.01% 6510
2016
Q4 		$19K Buy
15,639
+15,027
+2,455% +$16.9K ﹤0.01% 6022
2016
Q3 		$1K Buy
612
+17
+3% +$22 ﹤0.01% 6445
2016
Q2 		$1K Buy
595
+578
+3,400% +$762 ﹤0.01% 6446
2016
Q1 		$0 Hold
17
– – ﹤0.01% 6724
2015
Q4 		$0 Buy
+17
New +$76 ﹤0.01% 6802
2015
Q3 		– Sell
-16
Closed – – 6731
2015
Q2 		$0 Buy
+16
New +$132 ﹤0.01% 6756

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley's VKTX Position: Q1 2026 in Review

Morgan Stanley reduced its Viking Therapeutics (VKTX) stake by 2% in Q1 2026, selling an estimated $2M and leaving 3,013,928 shares worth $98.1M. The position accounts for 0.01% of the portfolio, ranked #1461.

Morgan Stanley first reported a position in VKTX in Q2 2015 and has held it in 40 quarters since. The position peaked at $119M in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Morgan Stanley held 3,013,928 shares of Viking Therapeutics worth $98.1M as of Q1 2026.
  • Morgan Stanley sold 62,342 Viking Therapeutics shares in Q1 2026, an estimated $2M.
  • Viking Therapeutics made up 0.01% of Morgan Stanley's portfolio in Q1 2026, its #1461 holding.
  • Morgan Stanley first reported a position in Viking Therapeutics in Q2 2015 and has held it in 40 quarters since.
  • Morgan Stanley's Viking Therapeutics position peaked at $119M in Q3 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.